Literature DB >> 3794096

Activation of the fibrinolytic system during intracoronary streptokinase administration.

A J Six, E J Brommer, E J Müller, H F Kerkhoff.   

Abstract

Serial biochemical studies were performed in 12 patients treated with intracoronary streptokinase infusion for acute myocardial infarction, in order to study the method of activation of the fibrinolytic system during local administration of a relatively low dose of this drug and to determine correlations between systemic effects and reperfusion. Plasma samples were obtained before and every 15 minutes during the infusion of streptokinase and after completion of the therapy. Streptokinase dosage in this study was 211,000 +/- 88,000 IU (+/- SD). The average time from the onset of symptoms to the start of infusion was 2 hours 50 minutes (range 1 hour 10 minutes to 3 hours 30 minutes). Reperfusion occurred in six patients and temporary recanalization in three; in three patients no recanalization was achieved. Fibrinolytic assays of pretreatment plasma samples revealed elevated levels of plasminogen activators, presumably caused by the release of tissue-type plasminogen activator after a condition of stress. Plasminogen concentrations decreased from 94 +/- 17% to 44 +/- 30%. Alpha 2-antiplasmin fell from 84 +/- 27% to 12 +/- 19%; in seven patients no plasmin inhibitor activity was measurable at the completion of the infusion. Free plasmin occurred in samples only when this inhibitor had disappeared. This resulted in a lytic state leading to degradation of fibrinogen, the levels of which fell from 2.9 +/- 0.7% to 1.5 +/- 1.1%. Fibrinogen degradation products, measured in plasma with monoclonal antibodies, increased exponentially during streptokinase infusion in at least four patients.(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3794096     DOI: 10.1016/s0735-1097(87)80100-6

Source DB:  PubMed          Journal:  J Am Coll Cardiol        ISSN: 0735-1097            Impact factor:   24.094


  4 in total

1.  Reprogrammed streptokinases develop fibrin-targeting and dissolve blood clots with more potency than tissue plasminogen activator.

Authors:  I Y Sazonova; R A McNamee; A K Houng; S M King; L Hedstrom; G L Reed
Journal:  J Thromb Haemost       Date:  2009-06-30       Impact factor: 5.824

Review 2.  Intravenous streptokinase. A reappraisal of its therapeutic use in acute myocardial infarction.

Authors:  K L Goa; J M Henwood; J F Stolz; M S Langley; S P Clissold
Journal:  Drugs       Date:  1990-05       Impact factor: 9.546

Review 3.  Streptokinase. A review of its pharmacology and therapeutic efficacy in acute myocardial infarction in older patients.

Authors:  P E Battershill; P Benfield; K L Goa
Journal:  Drugs Aging       Date:  1994-01       Impact factor: 3.923

4.  Fibrinolytic therapy in patients with ST-segment elevation myocardial infarction: Accelerated versus standard Streptokinase infusion regimen.

Authors:  Ahmed Bendary; Wael Tawfik; Mohamed Mahrous; Mohamed Salem
Journal:  J Cardiovasc Thorac Res       Date:  2017-12-30
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.